Patents by Inventor Takako Niwa
Takako Niwa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240269255Abstract: Provided are lipid particles encapsulating a nucleic acid capable of expressing an E6 antigen and an E7 antigen of human papillomavirus, whereby a vaccine for preventing and/or treating infection with human papillomavirus type 6 and/or type 11 can be provided. The lipid particles comprise a lipid that is a cationic lipid having the general formula (Ia), or a pharmaceutically acceptable salt thereof. [In the formula, R1, R2, p, L1 and L2 are as defined in the specification.Type: ApplicationFiled: May 18, 2022Publication date: August 15, 2024Inventors: Yoshikuni ONODERA, Sumika TANOUE, Takako NIWA, Makoto KOIZUMI
-
Publication number: 20240238404Abstract: Provided is a vaccine for preventing and/or treating an infection with an influenza virus. The vaccine comprises lipid particles containing a nucleic acid capable of expressing a haemagglutinin (HA) protein of the influenza virus, wherein a lipid is a cationic lipid having general formula (Ia), or a pharmaceutically acceptable salt thereof. [In the formula, R1, R2, p, L1 and L2 are as defined in the specification.Type: ApplicationFiled: May 18, 2022Publication date: July 18, 2024Inventors: Takanori TOMOZAWA, Takako NIWA, Yukinobu NUMATA, Makoto KOIZUMI
-
Publication number: 20240238407Abstract: Provided is a vaccine for preventing and/or treating infection with human T-cell leukemia virus type 1 (HTLV-1). A lipid particle encapsulating a nucleic acid expressing a gp46 antigen or a Tax antigen of human T-cell leukemia virus type 1 (HTLV-1), wherein the lipid comprises a cationic lipid represented by general formula (Ia): or a pharmaceutically acceptable salt thereof, wherein R1 and R2 each independently represent a C1-C3 alkyl group; L1 represents a C17-C19 alkenyl group optionally having one or more C2-C4 alkanoyloxy groups; L2 represents a C10-C19 alkyl group optionally having one or more C2-C4 alkanoyloxy groups, or a C10-C19 alkenyl group optionally having one or more C2-C4 alkanoyloxy groups; and p is 3 or 4.Type: ApplicationFiled: May 18, 2022Publication date: July 18, 2024Inventors: Ken ISHII, Takuya FUKUSHIMA, Yuetsu TANAKA, Fumihiko TAKESHITA, Makoto KOIZUMI, Takako NIWA, Shoko NOGUSA, Nao JONAI, Yoshikuni ONODERA
-
Publication number: 20230248819Abstract: The present invention provides a vaccine for preventing and/or treating infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The present invention relates to a lipid particle encapsulating a nucleic acid molecule capable of expressing the S protein and/or a fragment thereof of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the lipid comprises a cationic lipid represented by general formula (Ia) or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each independently represent a C1-C3 alkyl group; L1 represents a C17-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups; L2 represents a C10-C19 alkyl group which may have one or a plurality of C2-C4 alkanoyloxy groups or a C10-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups; and p is 3 or 4.Type: ApplicationFiled: June 10, 2021Publication date: August 10, 2023Inventors: Yoshihiro KAWAOKA, Masaki IMAI, Seiya YAMAYOSHI, Ken ISHII, Kouji KOBIYAMA, Eiko NAMBA, Tatsuya OKA, Miyuki TOZUKA, Nao JONAI, Yoshikuni ONODERA, Fumihiko TAKESHITA, Takashi SUZUKI, Takako NIWA, Makoto KOIZUMI, Kensuke NAKAMURA
-
Publication number: 20220409540Abstract: The present invention provides a vaccine for preventing and/or treating infections with human papillomavirus. The present invention relates to a lipid particle encapsulating a nucleic acid molecule capable of expressing the E6 and E7 antigens of human papillomavirus, wherein the lipid comprises a cationic lipid represented by general formula (Ia) or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each independently represent a C1-C3 alkyl group; L1 represents a C17-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups; L2 represents a C10-C19 alkyl group which may have one or a plurality of C2-C4 alkanoyloxy groups or a C10-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups; and p is 3 or 4.Type: ApplicationFiled: November 13, 2020Publication date: December 29, 2022Inventors: Takako NIWA, Takashi SUZUKI, Makoto KOIZUMI, Nao JONAI, Yoshikuni ONODERA, Fumihiko TAKESHITA, Ken ISHII
-
Patent number: 11015202Abstract: The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3?-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and ?-1,3-glucan.Type: GrantFiled: December 20, 2018Date of Patent: May 25, 2021Assignees: NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION, DAIICHI SANKYO COMPANY, LIMITEDInventors: Ken Ishii, Kouji Kobiyama, Taiki Aoshi, Fumihiko Takeshita, Yuji Kasuya, Takako Niwa, Makoto Koizumi
-
Patent number: 10731159Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.Type: GrantFiled: November 22, 2019Date of Patent: August 4, 2020Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Makoto Koizumi, Yoshiyuki Onishi, Takako Niwa, Masakazu Tamura, Yuji Kasuya
-
Publication number: 20200080086Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.Type: ApplicationFiled: November 22, 2019Publication date: March 12, 2020Inventors: Makoto KOIZUMI, Yoshiyuki ONISHI, Takako NIWA, Masakazu TAMURA, Yuji KASUYA
-
Patent number: 10533176Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.Type: GrantFiled: October 30, 2017Date of Patent: January 14, 2020Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Makoto Koizumi, Yoshiyuki Onishi, Takako Niwa, Masakazu Tamura, Yuji Kasuya
-
Publication number: 20190112606Abstract: The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3?-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and ?-1,3-glucan.Type: ApplicationFiled: December 20, 2018Publication date: April 18, 2019Applicants: NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION, DAIICHI SANKYO COMPANY, LIMITEDInventors: Ken ISHII, Kouji KOBIYAMA, Taiki AOSHI, Fumihiko TAKESHITA, Yuji KASUYA, Takako NIWA, Makoto KOIZUMI
-
Patent number: 10202606Abstract: The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3?-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and ?-1,3-glucan.Type: GrantFiled: September 19, 2014Date of Patent: February 12, 2019Assignees: NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION, DAIICHI SANKYO COMPANY, LIMITEDInventors: Ken Ishii, Kouji Kobiyama, Taiki Aoshi, Fumihiko Takeshita, Yuji Kasuya, Takako Niwa, Makoto Koizumi
-
Publication number: 20180051285Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.Type: ApplicationFiled: October 30, 2017Publication date: February 22, 2018Inventors: Makoto KOIZUMI, Yoshiyuki ONISHI, Takako NIWA, Masakazu TAMURA, Yuji KASUYA
-
Patent number: 9803199Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.Type: GrantFiled: July 7, 2014Date of Patent: October 31, 2017Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Makoto Koizumi, Yoshiyuki Onishi, Takako Niwa, Masakazu Tamura, Yuji Kasuya
-
Publication number: 20160257951Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.Type: ApplicationFiled: July 7, 2014Publication date: September 8, 2016Inventors: Makoto KOIZUMI, Yoshiyuki ONISHI, Takako NIWA, Masakazu TAMURA, Yuji KASUYA
-
Publication number: 20160208260Abstract: The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3?-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and ?-1,3-glucan.Type: ApplicationFiled: September 19, 2014Publication date: July 21, 2016Applicants: NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEAL TH AND NUTRITION, DAIICHI SANKYO COMPANY, LIMITEDInventors: Ken ISHII, Kouji KOBIYAMA, Taiki AOSHI, Fumihiko TAKESHITA, Yuji KASUYA, Takako NIWA, Makoto KOIZUMI
-
Patent number: 9155648Abstract: Disclosed herein is a stent delivery system which includes: a hollow shaft; first and second expandable balloons arranged around of the distal end of the shaft; and a stent which is arranged around the second balloon such that it expands as the second balloon expands; the first balloon having drug release means for releasing a drug at least to prevent the proliferation of endothelial cells, the stent being a bare metal stent to be indwelled at a target position as lesion of stenosis or occlusion in the lumen of a living body.Type: GrantFiled: February 24, 2014Date of Patent: October 13, 2015Assignee: TERUMO KABUSHIKI KAISHAInventor: Takako Niwa
-
Publication number: 20140172114Abstract: Disclosed herein is a stent delivery system which includes: a hollow shaft; first and second expandable balloons arranged around of the distal end of the shaft; and a stent which is arranged around the second balloon such that it expands as the second balloon expands; the first balloon having drug release means for releasing a drug at least to prevent the proliferation of endothelial cells, the stent being a bare metal stent to be indwelled at a target position as lesion of stenosis or occlusion in the lumen of a living body.Type: ApplicationFiled: February 24, 2014Publication date: June 19, 2014Applicant: Terumo Kabushiki KaishaInventor: Takako Niwa
-
Publication number: 20120245670Abstract: Disclosed herein is a stent delivery system which includes: a hollow shaft; first and second expandable balloons arranged around of the distal end of the shaft; and a stent which is arranged around the second balloon such that it expands as the second balloon expands; the first balloon having drug release means for releasing a drug at least to prevent the proliferation of endothelial cells, the stent being a bare metal stent to be indwelled at a target position as lesion of stenosis or occlusion in the lumen of a living body.Type: ApplicationFiled: February 21, 2012Publication date: September 27, 2012Applicant: Terumo Kabushiki KaishaInventor: Takako NIWA
-
Publication number: 20110269942Abstract: The present invention relates to an immunoliposome preparation or a hydrophobic molecule-modified antibody having a therapeutic effect on cancer, autoimmune disease, or inflammatory disease. Specifically, the present invention relates to an immunoliposome or a hydrophobic molecule-modified antibody comprising, as a constituent, an antibody capable of inducing the apoptosis of cells expressing a death domain-containing receptor.Type: ApplicationFiled: August 4, 2008Publication date: November 3, 2011Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Koji Morita, Takako Niwa, Yuji Kasuya, Kimihisa Ichikawa, Hiroko Yoshida
-
Publication number: 20100209490Abstract: The present invention relates to an immunoliposome preparation having a therapeutic effect on cancer, autoimmune disease, or inflammatory disease. Specifically, the present invention relates to an immunoliposome comprising, as a constituent, an antibody capable of inducing the apoptosis of cells expressing a death domain-containing receptor.Type: ApplicationFiled: August 4, 2008Publication date: August 19, 2010Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Koji Morita, Takako Niwa, Kimihisa Ichikawa, Hiroko Yoshida